The Product; human placental alkaline phosphatase
Purified PLAP can be obtained from the human placenta, but it’s recombinant form will
be used for the planned human clinical trials, and later in the clinical practice.
Besides being non-toxic, its thermal stability and long half-life time in the
circulation (7-10 days) makes it an excellent candidate for clinical use.
In various animal models, multiple mechanisms mediate the positive effects of PLAP on
the maintenance of skeletal muscle proteins including promotion of survival and
proliferation of muscle cells through IGF-1 mediated mechanism as well as reduction
of loss of body weight, dyslipidemia, insulin resistance, and hyperinsulinemia.
All this work has resulted in 20 issued US and international patents.